Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva's CGRP Inhibitor Fails In Chronic Cluster Headaches, Continues In Episodic

Jun 15 2018

• By Mandy Jackson

Closed up finger on keyboard with word CLINICAL TRIALS

Related Content

Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?

May 15 2018

Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

May 09 2017

Teva acquires pain company Labrys for $825m

Jun 04 2014

Teva Pushes CGRP Timeline Back To End Of 2018

May 03 2018

Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead

Jun 01 2018

Related Companies

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

Amgen, Inc.

Novartis AG

Celltrion, Inc.

Pfizer Inc.

Pfizer Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Neurology BioPharmaceutical

More from Neurological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window